» Articles » PMID: 9240182

Glycosaminoglycans in Crystal-surface Binding Substances and Their Role in Calcium Oxalate Crystal Growth

Overview
Journal Br J Urol
Specialty Urology
Date 1997 Jul 1
PMID 9240182
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To clarify the role of glycosaminoglycans (GAGs) in crystal-surface binding substances (CSBS) on the growth of calcium oxalate crystals in urine.

Materials And Methods: Urine samples (24 h) were collected from healthy men (aged 25-42 years) and CSBS were obtained from the pooled urine samples. The CSBS were digested with heparitinase or proteinase and the inhibition of crystal growth assessed before and after enzyme digestion. Anion-exchange chromatography and high-performance liquid chromatography (HPLC) were used to determine the types of GAGs contained in the CSBS.

Results: The inhibitory activity of CSBS on crystal growth decreased with concentration when digested with heparitinase or proteinase. HPLC showed that CSBS contained a small amount of dermatan sulphate and abundant heparan sulphate, both of which inhibited crystal growth.

Conclusion: Both heparan sulphate and dermatan sulphate may inhibit calcium oxalate crystallization, the former being the predominant GAG in CSBS.

Citing Articles

study on heparin/poly-l-lysine-copper coating for surface functionalization of ureteral stent.

Awonusi B, Li J, Li H, Wang Z, Hu J, Yang K Regen Biomater. 2022; 9:rbac083.

PMID: 36338173 PMC: 9629973. DOI: 10.1093/rb/rbac083.


and studies on bacteria and encrustation resistance of heparin/poly-L-lysine-Cu nanoparticles coating mediated by PDA for ureteral stent application.

Awonusi B, Li J, Li H, Wang Z, Yang K, Zhao J Regen Biomater. 2022; 9:rbac047.

PMID: 35928999 PMC: 9345062. DOI: 10.1093/rb/rbac047.


Update on ureteral stent technology.

Lange D, Chew B Ther Adv Urol. 2011; 1(3):143-8.

PMID: 21789062 PMC: 3126057. DOI: 10.1177/1756287209341306.